A Phase II Study of Concurrent Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer

@article{Yao2012API,
  title={A Phase II Study of Concurrent Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer},
  author={X. Yao and J. Hosenpud and C. Chitambar and J. Charlson and Y. Cheng},
  journal={Journal of Cancer},
  year={2012},
  volume={3},
  pages={145 - 151}
}
  • X. Yao, J. Hosenpud, +2 authors Y. Cheng
  • Published 2012
  • Medicine
  • Journal of Cancer
  • Background: Neoadjuvant chemotherapy with concurrent docetaxel, doxorubicin and cyclophosphamide is commonly used for patients with locally advanced breast cancer. Epirubicin is another anthracycline used in breast cancer but the concurrent use of epirubicin and taxane is not well-established. We conducted a single institution, phase II study to assess the efficacy and safety of concurrent docetaxel, epirubicin and cyclophosphamide (TEC) as a neoadjuvant chemotherapy regimen in breast cancer… CONTINUE READING
    Dose-banding studies on oxaliplatin
    Locally Advanced Breast Cancer

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 13 REFERENCES